- Conditions
- Hepatocellular Carcinoma
- Interventions
- Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 30,991
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson's Disease
- Interventions
- Lokomat
- Device
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Visual Acuity
- Interventions
- etafilcon A with ketotifen, 1-Day ACUVUE
- Combination Product · Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Maitland, Florida • Tampa, Florida + 3 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Panobinostat, Bortezomib
- Drug
- Lead sponsor
- Anand Jillella
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Cardiovascular Disease Risk Factor
- Interventions
- Vitalis Cardio
- Behavioral
- Lead sponsor
- Lucas Carr
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Shock
- Interventions
- Cheetah NICOM® PLRT, USCOM ® (Ultrasound Cardiac Output Monitor), Inferior Vena Cava (IVC) Ultrasound Collapsibility, CURVES Questionnaire, Lactate Clearance, 500ml Normal Saline Bolus, Clinician Discretion Intravenous Fluid Management
- Device · Behavioral · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Migraine in Adults
- Interventions
- Static magnetic helmet
- Device
- Lead sponsor
- Marco Loggia
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Nicotine Use Disorder, Smoking Cessation, Smoking Cessation Intervention
- Interventions
- Enhanced Courage to Quit
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 26 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Clinician Communication Skills Training
- Interventions
- SOPHIE Simulation Training, Control Educational Materials
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Breastfeeding, Breastfeeding, Exclusive, Postpartum Depression
- Interventions
- Text-Based Support
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Smoking
- Interventions
- Mindfulness, Quit Line
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Smoking, Smoking Cessation, Motivation, Nicotine Dependence
- Interventions
- Nicotine Patch, Nicotine Gum, Motivational Interviewing, Smoking Reduction, No Intervention, Nicotine Patch + Nicotine Gum
- Drug · Behavioral · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Uveal Melanoma
- Interventions
- AEB071, MEK162
- Drug
- Lead sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Prostate Adenocarcinoma
- Interventions
- SBRT
- Radiation
- Lead sponsor
- GenesisCare USA
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2019
- U.S. locations
- 4
- States / cities
- Fort Myers, Florida • Plantation, Florida • Farmington Hills, Michigan + 1 more
- Conditions
- Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
- Interventions
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- North Coast Medical Activadose II
- Device
- Lead sponsor
- The Mind Research Network
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Parkinson Disease
- Interventions
- Intraoperative Behavioral Testing, Behavioral Testing
- Diagnostic Test
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Healthy Adult Subjects
- Interventions
- Methylnaltrexone bromide
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, capecitabine
- Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Stress, Quality, Anxiety, Resilience
- Interventions
- Stress Management and Resilience Training
- Behavioral
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Mountain Home, Idaho • Baltimore, Maryland • Las Vegas, Nevada + 2 more
- Conditions
- Epilepsy, Sudden Cardiac Death
- Interventions
- A change or titration in the current or frequency settings of the VNS therapy system.
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
- Interventions
- DR-01
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Irvine, California + 11 more
- Conditions
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
- Interventions
- AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Santa Rosa, California • West Hills, California + 10 more
- Conditions
- Primary Hyperoxaluria
- Interventions
- Genetic Analysis
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 902 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota